Hope for RA patients: drug may heal bone erosion
NCT ID NCT05955066
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether baricitinib, a JAK inhibitor, can heal bone erosion in people with active rheumatoid arthritis. Sixty adults with moderate-to-severe RA and at least one bone erosion will receive either baricitinib or a placebo for 24 weeks. The main goal is to see if the drug reduces erosion size, measured by a special CT scan.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Baricitinib (Olumiant) 4 mg daily
What this could lead to
If successful, this could show that JAK inhibitors help repair bone damage in rheumatoid arthritis, potentially leading to better long-term joint health.
What could go wrong
This is a small, early-phase study with only 60 participants, so results may not apply to everyone. The treatment may not heal bone erosion, and JAK inhibitors carry risks like infections and blood clots.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Chinese University of Hong Kong
RECRUITINGHong Kong, Hong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••